References

1. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207-218.

2. Plazonnet B, Grove J, Durr M, et al. Pharmacokinetics and biopharmaceutical aspects of some anti-glaucoma drugs. In: Saettone MF, Bucci M, Speiser P, eds. Ophthalmic Drug Delivery: Biopharmaceutical, Technological, and Clinical Aspects. New York: Springer-Verlag; 1987:117-119.

3. Wagner JG. Kinetics of pharmacologic response, I: proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol. 1968; 20:173-201.

4. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, ed. Pharmacology of the Eye. New York: Springer-Verlag; 1984:19-102. Handbook of Experimental Pharmacology; Vol 69.

5. Schoenwald RD. Ocular drug delivery pharmacokinetic considerations. Clin Phar-macokinet. 1990;18:255-269.

6. Schaeffer BE, Zadunaisky JA. Stimulation of chloride transport by fatty acids in corneal epithelium and relation to changes in membrane fluidity. Biochim Biophys Acta. 1979;556:131-143.

7. Schoenwald R. The control of drug bioavailability from ophthalmic dosage forms. In: Smolen VF, Ball LA, eds. Controlled Drug Bioavailability. New York: John Wiley & Sons; 1985;3:257-306.

Schoenwald RD. Ocular pharmacokinetics/pharmacodynamics. In: Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Dekker; 1993:83-110. Drugs and the Pharmaceutical Sciences; Vol 58.

Wagner JG. Half-life and volume of distribution. In: Biopharmaceutics and Relevant

Pharmacokinetics. Hamilton, IL: Drug Intelligence Publishing; 1979:52-53.

Holly FJ. Tear film physiology. Int Ophthalmol Clin. 1987;27:2-6.

Farris RL, Stuchell RN, Mandel ID. Basal and reflex human tear analysis, I: Physical measurements: osmolarity, basal volumes, and reflex flow rate. Ophthalmology.

1981;88:852-857.

Stuchell RN, Farris RL, Mandel ID. Basal and reflex human tear analysis, II: Chemical analysis: lactoferrin and lysozyme. Ophthalmology. 1981;88:858-861. Mishima S, Gasset A, Klyce SD Jr, et al. Determination of tear volume and tear flow. Invest Ophthalmol. 1966;5:264-276.

Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol. 1986;2:67-108.

Raviola G. The structural basis of the blood-ocular barriers. Exp Eye Res. 1977; 25(suppl):27-63.

Zaki I, Fitzgerald P, Hardy JG, et al. A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man. J Pharm Pharmacol. 1986;38: 463-466.

Mishima S. Clinical pharmacokinetics of the eye [Proctor lecture]. Invest Ophthalmol Vis Sci. 1981;21:504-541.

Chen KK, Poth EJ. Racial difference of the mydriatic action of ephedrines, cocaine and euphthalmine. J Pharmacol Exp Ther. 1929;36:429-445.

Lee VH, Smith RE. Effect of substrate concentration, product concentration, and peptides on the in vitro hydrolysis of model ester prodrugs by corneal esterases. J Ocul Pharmacol. 1985;1:269-278.

Lee VH, Chang SC, Oshiro CM, et al. Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation. CurrEyeRes. 1985;4:1117-1125.

Ariens EJ. Stereoselectivity, a natural aspect of molecular biology: a blind spot in clinical pharmacology and pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1988; 13:307-308.

Patil PN, Miller DD, Trendelenburg U. Molecular geometry and adrenergic drug activity. Pharmacol Rev. 1974;26:323-392.

Gabelt BT, Kaufman PL. Aqueous humor hydrodynamics. In: Kaufman PL, Alm A, eds. Adler's Physiology of the Eye Clinical Application. 10th ed. St Louis, MO: Mosby; 2003:237-289.

Brubaker RF. Measurement of uveoscleral outflow in humans. J Glaucoma. 2001; 10(suppl 1):S45-S48.

Chrai SS, Makoid MC, Eriksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333-338. Patton TF, Francoeur M. Ocular bioavailability and systemic loss of topically applied ophthalmic drugs. Am J Ophthalmol. 1978;85:225-229.

Huang TC, Lee DA. Punctal occlusion and topical medications for glaucoma. Am J Ophthalmol. 1989;107:151-155.

Zimmerman TJ, Sharir M, Nardin GF, et al. Therapeutic index of pilocarpine, car-bachol, and timolol with nasolacrimal occlusion. Am J Ophthalmol. 1992;114:1-7.

Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc. 1977;74:457-487.

Olejnik O. Conventional systems in ophthalmic drug delivery. In: Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Dekker; 1993:177-198. Drugs and the Pharmaceutical Sciences; Vol 58.

Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability, I: Evaluation of fluorometholone. J Pharm Sci. 1975;64:931-936.

Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci. 1980;69:391-394. Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability, II: Evaluation of pilocarpine. J Pharm Sci. 1977;66:1222-1228.

DeSantis LM, Patil PN. Pharmacokinetics. In: Mauger TF, Craig EL, eds. Havener's Ocular Pharmacology. 6th ed. St Louis, MO: CV Mosby Co; 1994:22-52. Mitra AK, Mickelson TJ. Mechanism of transcorneal permeation of pilocarpine. J Pharm Sci. 1988;77:771-775.

Norn MS. Tear fluid pH in normals, contact lens wearers, and pathological cases. Acta Ophthalmol. 1988;66:485-489.

Coles WH, Jaros PA. Dynamics of ocular surface pH. Br J Ophthalmol. 1984;68:549-552.

Van Ooteghem MM. Factors influencing the retention of ophthalmic solutions on the eye surface. In: Saettone MF, Bucci M, Speiser P, eds. Ophthalmic Drug Delivery: Biopharmaceutical, Technological, and Clinical Aspects. New York: Springer-Verlag; 1987:7.

Bar-Ilan A, Neumann R. Basic considerations of ocular drug-delivery systems. In: Zimmerman TJ, ed. Textbook of Ocular Pharmacology. Philadelphia, PA: LippincottRaven; 1997:139-150.

Patton TF, Robinson TR. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J Pharm Sci. 1975;64:1312-1316.

Burstein NL. Preservative alteration of corneal permeability in humans and rabbits. Invest Ophthalmol Vis Sci. 1984;25:1453-1457.

Hughes PM, Mitra AK. Overview of ocular drug delivery and iatrogenic ocular cy-topathologies. In: Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Dekker; 1993:1-27. Drugs and the Pharmaceutical Sciences; Vol 58. Fraunfelder FT. Drug-Induced Ocular Side Effects and Drug Interactions. Philadelphia, PA: Lea & Febiger; 1976.

Bar-Ilan A, Aviv H, Friedman D, et al. Improved performance of ocular drugs formulated in submicron emulsions. Invest Ophthalmol Vis Sci. 1993(suppl);34:1488. Roziere A, Mazuel C, Grove J, Plazonnet B. Gelrite: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles: effect on bioavailability of timolol. Int J Pharm. 1989;57:163-168.

Ibrahim H, Gurny R, Buri P, et al. Ocular bioavailability of pilocarpine from phase transition latex system triggered by pH. Eur J Drug Metab Pharmacokinet. 1990; 15(suppl):206.

Harsh DC, Gehrke SH. Controlling the swelling characteristics of temperature-sensitive cellulose ether hydrogels. J Controlled Release. 1991;17:175-185. Miller SC, Donovan MD. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharmacol. 1982;12:147-152.

Kumar S, Haglund BO, Himmelstein KJ. In situ-forming gels of ophthalmic drug delivery. J Ocul Pharmacol. 1994;10:47-56.

50. Heller J. Controlled drug release from monolithic systems. In: Saettone MF, Bucci M, Speiser P, eds. Ophthalmic Drug Delivery: Biopharmaceutical, Technological, and Clinical Aspects. New York: Springer-Verlag; 1987:179.

51. Bartlett JD, Cullen AP. Clinical administration of ocular drugs. In: Bartlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology. 2nd ed. Boston, MA: Butterworths; 1989:46-48.

52. Lamberts DW. Solid delivery devices. Int Ophthalmol Clin. 1980;20:63-77.

53. Bawa R. Ocular inserts. In: Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Dekker; 1993:232-234. Drugs and the Pharmaceutical Sciences; Vol 58.

54. Zimmerman TJ, Leader B, Kaufman HE. Advances in ocular pharmacology. Annu Rev Pharmacol Toxicol. 1980;20:415-428.

55. Quigley HA, Pollack IP, Harbin TS. Pilocarpine Ocuserts: long-term clinical trials and selected pharmacodynamics. Arch Ophthalmol. 1975;93:771-775.

56. Shell JW, Baker RW. Diffusional systems for controlled release of drugs to the eye. Ann Ophthalmol. 1974;6:1037-1043,1045.

57. Urquhart J. Development of the Ocusert pilocarpine ocular therapeutic systems: a case history in ophthalmic product development. In: Robinson JR, ed. Ophthalmic Drug Delivery Systems. Washington, DC: American Pharmaceutical Association; 1980:105.

58. Hitchings RA, Smith RJ. Experience with pilocarpine Ocuserts. Trans Ophthalmol Soc UK. 1977;97:202-205.

59. Drance SM, Mitchell DW, Schulzer M. The effects of Ocusert pilocarpine on anterior chamber depth, visual acuity and intraocular pressure in man. Can J Ophthalmol. 1977;12:24-28.

60. Francois J, Goes F, Zagorski Z. Comparative ultrasonographic study of the effect of pilocarpine 2% and Ocusert P 20 on the eye components. Am J Ophthalmol. 1978; 86:233-238.

61. Novak S, Stewart RH. The Ocusert system in the management of glaucoma. Tex Med. 1975;71:63-65.

62. Armaly MF, Rao KR. The effect of pilocarpine Ocusert with different release rates on ocular pressure. Invest Ophthalmol. 1973;12:491-496.

63. Weiner N, Martin F, Riaz M. Liposomes as a drug delivery system. Drug Dev Indust Pharm. 1989;15:1523-1554.

64. Schulman JA, Peyman GA. Intracameral, intravitreal and retinal drug delivery. In: Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Dekker; 1993:395397. Drugs and the Pharmaceutical Sciences; Vol 58.

65. Davis NM, Kellaway IW, Greaves JL, Wilson CG. Advanced corneal delivery systems: liposomes. In: Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Dekker; 1993:289-303. Drugs and the Pharmaceutical Sciences; Vol 58.

66. New RRC, Black CDV, Parker RJ, et al. Liposomes in biological systems. In: New RRC, ed. Liposome. Oxford: IRL Press at Oxford University; 1990:221.

67. Lee VH, Urrea PT, Smith RE, Schanzlin DJ. Ocular drug bioavailability from topically applied liposomes. Surv Ophthalmol. 1985;29:335-348.

68. Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci. 1982;22:220-227.

69. Juliano RL, Stamp D. Lectin-mediated attachment of glycoprotein-bearing liposomes to cells. Nature. 1976;261:235-238.

70. Barza M, Baum J, Szoka F Jr. Pharmacokinetics of subconjunctival liposome-encapsulated gentamicin in normal rabbit eyes. Invest Ophthalmol Vis Sci. 1984;25: 486-490.

71. Alghadyan AA, Peyman GA, Khoobehi B, et al. Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection. Int Ophthalmol. 1988;12:101-104.

72. Fishman PH, Peyman GA, Lesar T. Intravitreal liposome-encapsulated gentamicin in a rabbit model: prolonged therapeutic levels. Invest Ophthalmol Vis Sci. 1986;27:1103-1106.

73. Tremblay C, Barza M, Szoka F, et al. Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits. Invest Ophthalmol Vis Sci. 1985;26: 711-718.

74. Alghadyan AA, Peyman GA, Khoobehi B, et al. Liposome-bound cyclosporine: clearance after intravitreal injection. Int Ophthalmol. 1988;12:109-112.

75. Norley SG, Huang L, Rouse BT. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro. J Immunol. 1986;136:681-685.

76. Norley SG, Sendele D, Huang L, Rouse BT. Inhibition of herpes simplex virus replication in the mouse cornea by drug containing immunoliposomes. Invest Ophthalmol Vts Sci. 1987;28:591-595.

77. Alvarez-Lorenzo C, Hiratani H, Gomez-Amoza JL, et al. Soft contact lenses capable of sustained delivery of timolol. J Pharm Sci. 2002;91:2182-2192.

78. Alvarez-Lorenzo C, Concheiro A. Molecularly imprinted polymers for drug delivery. J Chromatogr B. 2004;804:231-245.

79. Ashton P, Blandford DL, Pearson PA, et al. Review: implants. J Ocul Pharmacol. 1994;10:691-701.

80. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol. 1992;110:255-258.

81. Martin DF, Ferris FL, Parks DJ, et al. Ganciclovir implant exchange: timing, surgical procedure, and complications. Arch Ophthalmol. 1997;115:1389-1394.

82. Jaffe GJ, Yang CS, Wang XC, et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46-56.

83. Enyedi LB, Pearson PA, Ashton P, Jaffe GJ. An intravitreal device providing sustained release of cyclosporine and dexamethasone. Curr Eye Res. 1996;15:549-557.

84. Smith TJ, Ashton P. Sustained-release subconjunctival 5-fluorouracil. Ophthalmic Surg Lasers. 1996;27:763-767.

85. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triam-cinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vi-treoretinopathy. Arch Ophthalmol. 1998;116:69-77.

86. Berger AS, Cheng CK, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretino-pathy. Invest Ophthalmol Vis Sci. 1996;37:2318-2325.

87. Lim LL, Smith JR, Rosenbaum JT. Retisert (Bausch & Lomb/control delivery system). Cur Opin Invest Drugs. 2005;6:1159-1167.

88. Fluocinolone acetonide ophthalmic-Bausch & Lomb: fluocinolone acetonide Envision TD implant. Drugs R D. 2005;6:116-119.

89. Chrousos GP. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung B ed. Basic and Clinical Pharmacology. 9th ed. New York: Large Medical Books/McGraw-Hill; 2004:641-660.

90. Francois J. Corticosteroid glaucoma. Ann Ophthalmol. 1977;9:1075-1080.

91. Cantrill HL, Palmberg, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79:1012-1017.

92. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of desamethasone in the normal eye. Arch Ophthalmol. 1963;70:482-491.

93. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of desamethasone on the glaucomatous eye. Arch Ophthalmol. 1963;70: 492-499.

94. Weinreb RN, Polansky JR, Kramer SG, et al. Acute effects of dexamethasone on introcular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985;26:170-175.

95. Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740-743.

96. Herschler J. Increased intraocular pressure induced by repository corticosteroids. Am J Ophthalmol. 1976;82:90-93.

97. Espildora J, Vicuna P, Diaz E. Cortisone-induced glaucoma: a report on 44 affected eyes. J Fr Ophthalmol. 1981;4:503-508.

98. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20:407-416.

This page intentionally left blank

0 0

Post a comment